Clinical, epidemiological, and economic profile of patients with Parkinson disease eligible for neuromodulation
Abstract
BackgroundParkinsons disease is a progressive neurodegenerative condition, often associated with motor complications, neuropsychiatric symptoms, and increased care costs in advanced stages. Neuromodulation, especially deep brain stimulation, represents a therapeutic alternative for selected patients.
ObjectiveTo characterize the clinical, epidemiological, therapeutic, and economic profile of patients with Parkinsons disease followed at a tertiary center and to estimate the proportion of individuals eligible for neuromodulation.
MethodsA cross-sectional descriptive study included 4,060 patients with idiopathic Parkinson disease followed from January 2022 to December 2025. Demographic data, clinical characteristics, functional scales, therapeutic regimen, eligibility criteria for neuromodulation, and cost-effectiveness estimates were analyzed. Comparisons with data from the literature were performed using appropriate statistical tests, considering a significance of p<0.05.
ResultsThe sample was predominantly male, with a median age of 69 years, and a median time of evolution of 8 years. Motor complications occurred in 58.4% of the patients, a frequency higher than that described in general populations. In all, 893 patients were considered eligible for neuromodulation, corresponding to 22.0% of the sample. The economic analysis estimated a reduction in annual costs after neuromodulation, with an average saving of R$ 8,247 per patient/year and an incremental cost-effectiveness ratio of R$ 46,505 per QALY.
ConclusionThe study population presented a clinical profile compatible with advanced Parkinsons disease, a high frequency of motor complications and a significant proportion of patients potentially eligible for neuromodulation. The data suggest a possible clinical and economic benefit of the structured incorporation of this therapeutic strategy.
Related
- Epidemiological patterns, clinical profiles and mortality outcomes of patients with heart failure: a retrospective, hospital-based, single-center study in northern Iran
- Clinico-Epidemiological Characteristics, Hospital Care Interventions, and Clinical Outcomes of Patients with SARS-CoV-2 in Nepal: The Mediating Role of Age
- Peripheral immunoinflammatory markers and clinical correlations in Parkinson's disease patients carrying LRRK2 G2385R and R1628P variants
- Interaction Between Exercise Intensity and Sedentary Behavior on VO2max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial
- Effects of exercise interventions on gait, motor function, and balance in patients with Parkinson’s disease: A meta-analysis with clinical implications
BibTeX
@misc{glinski2026clinical,
title = {{Clinical, epidemiological, and economic profile of patients with Parkinson disease eligible for neuromodulation}},
author = {T. A. Glinski and L. C. K. da Silva and J. L. R. N. da Luz and T. G. Rosa},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.05.26364767},
url = {https://www.medrxiv.org/content/10.64898/2026.10.05.26364767v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Clinical, epidemiological, and economic profile of patients with Parkinson disease eligible for neuromodulation
AU - T. A. Glinski
AU - L. C. K. da Silva
AU - J. L. R. N. da Luz
AU - T. G. Rosa
PY - 2026
DA - 2026/10/05
PB - medRxiv
DO - 10.64898/2026.10.05.26364767
UR - https://www.medrxiv.org/content/10.64898/2026.10.05.26364767v1
AB - BackgroundParkinsons disease is a progressive neurodegenerative condition, often associated with motor complications, neuropsychiatric symptoms, and increased care costs in advanced stages. Neuromodulation, especially deep brain stimulation, represents a therapeutic alternative for selected patients. ObjectiveTo characterize the clinical, epidemiological, therapeutic, and economic profile of patients with Parkinsons disease followed at a tertiary center and to estimate the proportion of individuals eligible for neuromodulation. MethodsA cross-sectional descriptive study included 4,060 patients with idiopathic Parkinson disease followed from January 2022 to December 2025. Demographic data, clinical characteristics, functional scales, therapeutic regimen, eligibility criteria for neuromodulation, and cost-effectiveness estimates were analyzed. Comparisons with data from the literature were performed using appropriate statistical tests, considering a significance of p<0.05. ResultsThe sample was predominantly male, with a median age of 69 years, and a median time of evolution of 8 years. Motor complications occurred in 58.4% of the patients, a frequency higher than that described in general populations. In all, 893 patients were considered eligible for neuromodulation, corresponding to 22.0% of the sample. The economic analysis estimated a reduction in annual costs after neuromodulation, with an average saving of R$ 8,247 per patient/year and an incremental cost-effectiveness ratio of R$ 46,505 per QALY. ConclusionThe study population presented a clinical profile compatible with advanced Parkinsons disease, a high frequency of motor complications and a significant proportion of patients potentially eligible for neuromodulation. The data suggest a possible clinical and economic benefit of the structured incorporation of this therapeutic strategy.
ER -